Eric Padron, MD (PI) is an Associate Member in the Malignant Hematology Department at the H. Lee Moffitt Cancer Center with a research focus in chronic myeloid neoplasms (CMNs). His applied translational laboratory seeks to identify and implement novel discoveries directly to the clinic. Although mechanistic studies to understand the molecular underpinnings of chronic myelomonocytic leukemia (CMML), a subtype of CMNs, constitute a large portion of his laboratory’s efforts, his laboratory singularly views these insights as tools for translation to the clinic to improve the management of patients with CMNs. This urgency is born out of Dr. Padron’s CMN clinic in which most of his patients succumb to their disease. He has been awarded several grants for his genomic studies in the MDS and CMML fields, including the American Society of Hematology Scholar Award, the Evans MDS Foundation Fellow Award, the NCI to study the therapeutic candidacy of long noncoding RNAs, and a large MDS Foundation grant to study molecular aspects of CMML in 1000 patients. Dr. Padron has successfully translated his lab discoveries into several trials in the CMML clinic. This is exemplified by his benchto-bedside efforts that have led to the successful completion of a phase 1 and 2 trial testing ruxolitinib in CMML. Dr. Padron has published over 150 peer-reviewed manuscripts in the area of myeloid malignancies. Importantly, Dr Padron was recently awarded an R37 NCI grant to develop a CMML PDX model that can recapitulate the human condition. These efforts, and his laboratory's major interest in cytokines and their role in disease progression, are in line with the the expected efforts and duties of the T32 application.